GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » ROE %

Beijing Luzhu Biotechnology Co (HKSE:02480) ROE % : -22.20% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Beijing Luzhu Biotechnology Co's annualized net income for the quarter that ended in Jun. 2024 was HK$-236.71 Mil. Beijing Luzhu Biotechnology Co's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was HK$1,066.40 Mil. Therefore, Beijing Luzhu Biotechnology Co's annualized ROE % for the quarter that ended in Jun. 2024 was -22.20%.

The historical rank and industry rank for Beijing Luzhu Biotechnology Co's ROE % or its related term are showing as below:

HKSE:02480' s ROE % Range Over the Past 10 Years
Min: -489.09   Med: -257.16   Max: -17.8
Current: -17.8

During the past 4 years, Beijing Luzhu Biotechnology Co's highest ROE % was -17.80%. The lowest was -489.09%. And the median was -257.16%.

HKSE:02480's ROE % is ranked better than
66.62% of 1300 companies
in the Biotechnology industry
Industry Median: -42.14 vs HKSE:02480: -17.80

Beijing Luzhu Biotechnology Co ROE % Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co ROE % Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
ROE %
- -489.09 -25.22 -17.72

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROE % Get a 7-Day Free Trial -15.60 -15.05 -31.30 -22.20 -12.91

Competitive Comparison of Beijing Luzhu Biotechnology Co's ROE %

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Luzhu Biotechnology Co's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's ROE % distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's ROE % falls into.


;
;

Beijing Luzhu Biotechnology Co ROE % Calculation

Beijing Luzhu Biotechnology Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-272.734/( (1046.882+1116.341)/ 2 )
=-272.734/1081.6115
=-25.22 %

Beijing Luzhu Biotechnology Co's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=-236.706/( (1116.341+1016.465)/ 2 )
=-236.706/1066.403
=-22.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


Beijing Luzhu Biotechnology Co  (HKSE:02480) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-236.706/1066.403
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-236.706 / 0)*(0 / 1231.352)*(1231.352 / 1066.403)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.1547
=ROA %*Equity Multiplier
=N/A %*1.1547
=-22.20 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-236.706/1066.403
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-236.706 / -236.706) * (-236.706 / -254.104) * (-254.104 / 0) * (0 / 1231.352) * (1231.352 / 1066.403)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9315 * N/A % * 0 * 1.1547
=-22.20 %

Note: The net income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Beijing Luzhu Biotechnology Co ROE % Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Luzhu Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is its Core Product.
Executives
Kong Jian 2101 Beneficial owner
Zhang Yanping 2202 Interest of your spouse
Ma Jianan 2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo 2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
China Construction Bank Corporation 2201 Interest of corporation controlled by you
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Peng Ling 2201 Interest of corporation controlled by you
Ma Biao 2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co Headlines

No Headlines